Search

everythinglearnresearchcommunity

for

Search:↓

FOL-005, a new substance, was found to reduce hair growth without toxicity when injected into skin, suggesting it could be used to treat excessive hair growth.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.

Rituximab improved her dermatomyositis better than usual treatments.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Oral tacrolimus may be a potential treatment for hair loss that doesn't respond to corticosteroids.

Injectable hyaluronic acid can effectively treat facial lipoatrophy from lupus panniculitis.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

Itraconazole-loaded nanoparticles are more effective and less toxic for treating fungal infections than conventional oral itraconazole.

SM04755 may be an effective topical treatment for psoriasis.

TNF-inhibitor induced alopecia can be treated effectively with different therapies.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

Mycophenolate mofetil may improve symptoms and stop hair loss in Lichen planopilaris, but more research is needed.

BMS-470539 reduces skin fibrosis and inflammation.

Etanercept effectively treated a severe skin condition when other treatments failed.

Tideglusib may help bone regeneration without being toxic at low doses.

Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.

Dupilumab may help regrow hair in people with severe alopecia.

Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.

Stilbamidine and hydroxystilbamidine inhibit enzyme release from lysosomes and have effects similar to cortisol and chloroquine.

Lugol's solution can cause thyroid problems if used long-term for non-approved reasons.

Detoxil effectively treats chronic skin conditions by improving liver detoxification and reducing symptoms.

Certain liver diseases respond well to specific treatments and have varying risks for liver cancer.

The lotion with equol, dihomo-γ-linolenic acid, and propionyl-l-carnitine was effective in reducing hair loss in men and women.

Deferasirox effectively reduces iron overload in ß-thalassemia patients but may cause some manageable side effects.

The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.